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c Department of Psychiatry and Psychotherapy, Semmelweis University, Balassa Street 8, H-1085, Budapest, Hungary 
d Endeavor Psychology, 10 Newbury Street, Boston, MA, 02116, USA   
A R T I C L E  I N F O   
Keywords: 
Alcohol withdrawal syndrome 





A B S T R A C T   
Background: Although the Clinical Institute Withdrawal Assessment for Alcohol – Revised (CIWA-Ar) is a gold 
standard tool for the clinical evaluation of alcohol withdrawal syndrome (AWS), a systematic analysis using the 
total scores of the CIWA-Ar as a means of an objective follow-up of the course and treatment of AWS is missing. 
The aims of the present study were to systematically evaluate scientific data using the CIWA-Ar, to reveal 
whether the aggregated CIWA-Ar total scores follow the course of AWS and to compare benzodiazepine (BZD) 
and non-benzodiazepine (nBZD) therapies in AWS. 
Methods: 1054 findings were identified with the keyword “ciwa” from four databases (PubMed, ScienceDirect, 
Web of Science, Cochrane Registry). Articles using CIWA-Ar in patients treated with AWS were incorporated and 
two measurement intervals (cumulative mean data of day 1− 3 and day 4− 9) of the CIWA-Ar total scores were 
compared. Subgroup analysis based on pharmacotherapy regimen was conducted to compare the effectiveness of 
BZD and nBZD treatments. 
Results: The random effects analysis of 423 patients showed decreased CIWA-Ar scores between the two mea-
surement intervals (BZD: d = –1.361; CI: –1.829 < δ < –0.893; nBZD: d = –0.858; CI: –1.073 < δ < –0.643). 
Sampling variances were calculated for the BZD (v1 = 0.215) and the nBZD (v2 = 0.106) groups, which indicated 
no significant group difference (z = − 1.532). 
Conclusions: Our findings support that the CIWA-Ar follows the course of AWS. Furthermore, nBZD therapy has a 
similar effectiveness compared to BZD treatment based on the CIWA-Ar total scores.   
1. Introduction 
Alcohol use disorder (AUD) is a global health problem ranking sev-
enth among the leading causes of death (GBD 2016 Alcohol Collabora-
tors, 2018). Generally, patients with AUD are admitted to hospitals due 
to the long-term consequences of alcohol use, such as liver insufficiency, 
polyneuropathy or alcohol withdrawal syndrome (AWS). AWS may 
occur in the hospital treatment of AUD patients after the rapid reduction 
or cessation of alcohol consumption (Sachdeva et al., 2015; Saitz, 2005). 
AWS typically starts within 6− 24 hours after the last alcohol intake 
(Hall and Zador, 1997) and the characteristic symptoms include 
insomnia, autonomic symptoms (e.g. sweating or tachycardia), tremors, 
nausea and/or vomiting, psychomotor agitation, anxiety, seizures and 
perceptual disturbances (auditory, tactile or visual) (American Psychi-
atric Association, 2013). The main goals during the treatment of AWS 
are to reduce the symptoms of withdrawal and to prevent the develop-
ment of severe consequences such as withdrawal seizures and/or 
delirium tremens (DT). There is a consensus that the clinical description 
of AWS divides the first 6− 72 hours based on the symptom severity of 
withdrawal and the possibility of the emergence of severe complications 
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such as withdrawal seizure or DT from the complete course of AWS, 
which may last up to 2 weeks (Haber et al., 2009). 
Although AWS is basically a clinical diagnosis, in the last few de-
cades, several psychometric tools were recommended to identify and 
follow the signs of it (Elefante et al., 2020; Gray et al., 2010; Lindner 
et al., 2019; Sullivan et al., 1989). Objective measurements for moni-
toring the course and severity of AWS are necessities, from which the 
revised version of the Clinical Institute Withdrawal Assessment for 
Alcohol (CIWA-Ar) was the first scale that was developed to monitor and 
rate the number and severity of symptoms occurring during AWS. Its 10 
items reflect on symptom groups of AWS including the leading symp-
toms of the syndrome. The items of the CIWA-Ar include nausea, vom-
iting, tremor, paroxysmal sweats, perceptual (tactile, visual or auditory) 
disturbances, anxiety, agitation, headache and disturbances of orienta-
tion and/or consciousness (Sullivan et al., 1989). Clinician-rated scoring 
is made for each item by a Likert-scale and the maximum attainable 
score is 67, where the higher score reflects on the more severe AWS 
(Bakhla et al., 2014; Higgins et al., 2019; Pittman et al., 2007), and the 
CIWA-Ar scores show a higher internal consistency during the first phase 
of AWS, during which the more severe symptoms occur (Lázár et al., 
2019). 
Over the last decades, the CIWA-Ar has been translated into various 
languages and several reports have revealed its psychometric properties 
and distinct factor structures in different countries (Davis et al., 2018; 
Eloma et al., 2018; Lázár et al., 2019; Rappaport et al., 2013). Despite 
the fact that several modified versions of the CIWA-Ar have been 
introduced in the scientific literature (Bakhla et al., 2014; Elefante et al., 
2020; Gray et al., 2010; Higgins et al., 2019; Lindner et al., 2019; 
Maldonado et al., 2014; Pittman et al., 2007) and shorter versions of the 
scale have also been suggested (Elefante et al., 2020; Gray et al., 2010; 
Lindner et al., 2019; Maldonado et al., 2014), national guidelines such as 
protocols of the National Institute for Health and Care Excellence (NICE) 
and the National Institutes of Health (NIH) recommend the CIWA-Ar as 
the gold standard tool in the management of AWS. Based on these 
findings, it was proposed that the CIWA-Ar scores could be suitable for 
clinicians to make a treatment regimen for AWS. Some findings sug-
gested that the CIWA-Ar scores of 0–8, 9–15 and 16 or more indicate 
mild, moderate, and severe withdrawal syndrome, respectively 
(Mayo-Smith, 1997; Saitz and O’Malley, 1997). For instance, patients 
with mild withdrawal symptoms (scores of 8 or less) can be managed 
without pharmacotherapy. 
Concerning these, clinical management of AWS are centered around 
the following pharmacotherapeutic treatment regimens: symptom- 
triggered and fixed-schedule therapies. Symptom-triggered treatment, 
which is a CIWA-Ar-based regimen, is defined as an approach in which 
patients are consistently monitored by the CIWA-Ar, and the designation 
of adequate pharmacotherapy is only used in case symptoms of with-
drawal cross a certain threshold of severity. In this treatment regimen, 
further dosages and the times of reassessments are also based on the 
score of the structured assessment scale. Whereas a fixed-dose regimen is 
characterized by giving the patient a previously determined dose of 
medication in formerly established (i.e., fixed) time intervals based on a 
schedule. The amount of received doses gradually decrease over time; 
also, the fixed-dose regimen may be modified according to withdrawal 
symptom severity, in case the predetermined fixed-dose would prove to 
be inadequate in controlling withdrawal symptoms (Wong et al., 2020). 
Previous scientific works have demonstrated that symptom-triggered 
therapy, which is a CIWA-Ar-based regimen, showed better effective-
ness compared to fixed-schedule therapy (Cassidy et al., 2012; Daeppen 
et al., 2002; Ismail et al., 2019; Jaeger et al., 2001; Reoux and Miller, 
2000; Sachdeva et al., 2014). 
Benzodiazepines (BZDs) such as diazepam, lorazepam, chlordiaz-
epoxide or oxazepam are predominantly regarded as symptom-triggered 
therapies and are first choices in the treatment of AWS (Weintraub, 
2017). The efficacy of the subclasses of BZDs are similar; however, 
long-acting drugs such as diazepam and chlordiazepoxide are the more 
preferred choices. Additionally, it has been suggested that diazepam is 
superior in the treatment of AWS (Weintraub, 2017). Despite that BZDs 
are the drugs of choice in the treatment of AWS, it is important to note 
that they have a relatively high addictive potential (Weintraub, 2017). 
For this reason, other agents such as anticonvulsant, adrenergic drugs 
and barbiturates were approved by the Food and Drug Administration 
(FDA), which are also used and recommended during the course of AWS. 
In summary, the CIWA-Ar is the most commonly used tool to identify 
and follow the course of withdrawal symptoms. Furthermore, the 
symptom-triggered therapy of AWS with BZDs using the CIWA-Ar is 
considered to be the gold standard for the treatment of uncomplicated 
and complicated (with DT and/or withdrawal seizure) withdrawal 
syndrome. Based on our literature search, the course of AWS and its 
treatment options using the CIWA-Ar total score as a means of an 
objective follow-up of the course and treatment of AWS has not been 
systematically evaluated yet. Consequently, the aims of the present 
systematic review-based meta-analysis were 1) to explore and system-
atically evaluate the empirical data presenting the CIWA-Ar total scores, 
2) to assess whether the CIWA-Ar is suitable for following the course of 
AWS during pharmacotherapeutic treatment, and 3) to compare BZD 
and FDA-approved nBZD treatments in patients with AWS. 
2. Material and methods 
2.1. Search strategy and study selection 
Three authors (I.K.P., B.A. and I.K.) independently systematically 
searched four databases (PubMed, ScienceDirect, Web of Science and 
Cochrane Registry) in order to identify studies published before January 
31, 2020, which documented the severity of AWS with the CIWA-Ar in 
patients treated with AWS. The full-text search was made without 
filtering, “ciwa” was used as the key search term. Our systematic liter-
ature search yielded 1054 articles for possible inclusion in the quanti-
tative meta-analysis. The first author (I.K.P.) listed the previously 
identified scientific articles for critical revision of a professional 
researcher team expert in the course and pharmacotherapy of AWS, in 
clinical psychometrics, and in the methodology of meta-analyses (I.K.P., 
I.K., B.A. and B.A.L.). During this process, duplicates (N = 209) and grey 
literature (e.g. conference abstracts, correspondence, editorial letters 
and RCT registrations) (N = 176) were removed. Non-English articles (N 
= 58) and publications not connected to AWS (N = 62) were also 
excluded. Investigations of specific populations were selected out (N =
5), since the comorbid somatic state affects the course and treatment of 
AWS. In this sense, Kong et al. (2017) and Spies et al. (1995; 1998) have 
examined alcohol dependent patients with carcinoma, Talbot (2011) 
have investigated patients developing Wernicke’s disease in jail setting 
and Illig et al. (2001) have explored the unexpected emergence of AWS 
following aortic surgery. Several articles (N = 70) were excluded 
because of the use of different versions of the CIWA-Ar (CIWA-A, 
CIWA-Benzodiazepine or other modified versions). Non-empirical 
studies (e.g. indexes, author indexes, table of contents, abbreviations, 
appendixes, reviews, case reports, protocols, guidelines etc.) were also 
removed (N = 219). Articles not monitoring the course of AWS (e.g. the 
CIWA-Ar was applied as a screening test and only one assessment point 
was reported) (N = 71), and the lack of use of the CIWA-Ar total scores 
(N = 92) were excluded. Additionally, 12 papers fell out due to 
non-eligibility based on medication. These were the following: patients 
with AWS were treated with augmented medications (concurrent com-
bination of multiple BZDs and nBZDs) in case of numerous studies 
(Djokić et al., 2011; Jegham, Cunelle and Matthys, 2018; Love and 
Zimmerman, 2020), and patients received several BZDs in the study of 
Jaeger, Lohr and Pankratz (2001). In the study of Karst et al. (2002) 
patients received nBZD and acupuncture or nBZD and placebo 
acupuncture. This study was excluded because acupuncture treatment is 
a non-chemical therapy, and it can only be considered as an alternative 
therapeutic approach. Additionally, Wilhelm et al. (2011) and 
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Narendran et al. (2018) have not clarified the type and the dosing of the 
medications. In the study of Nadkarni et al. (2020), patients were treated 
by home detoxification and the exact type and dosing of pharmaco-
therapy was also not detailed. The studies of Kumar, Andrade and 
Murthy (2009); Silpakit et al. (1999), and Ramanujam et al. (2015) were 
also excluded due to their use of lorazepam or chlordiazepoxide, and 
since diazepam, as a first-line drug in the treatment of AWS, was in the 
main focus of the present meta-analysis. In the study of Mason et al. 
(2006), the patients did not receive any medications, except in cases of 
the emergence of severe AWS symptoms. Empirical publications were 
included in case they reported sample size, the means and standard 
deviations of the CIWA-Ar in patients with clinical diagnosis of AWS and 
used evidence-based treatments (especially diazepam [BZD] or other 
FDA-approved medications [nBZD]). Finally, reference lists of studies 
identified were hand-searched by the first author (I.K.P.) for potential 
inclusion, and after applying all the exclusion criteria aforementioned, 
11 studies met the previously set criteria for inclusion in the present 
meta-analysis (see Fig. 1). 
2.2. Meta-analysis: data extraction 
Since articles were excluded due to the lack of available CIWA-Ar 
means or standard deviations (N = 92), when we found an article that 
was potentially eligible for inclusion for our study but did not include 
the necessary means and standard deviations for the meta-analysis, we 
tried to contact the corresponding author two times over two months to 
ask them to provide these missing data. 
Our units of the data analysis were the means and standard de-
viations of the cumulative CIWA-Ar total scores, which were calculated 
during the course of AWS in nine days of treatment. The first phase of the 
AWS was defined as the aggregated means and standard deviations of 
the CIWA-Ar scores of day 1− 3; the second phase was identified as the 
means and standard deviations of the CIWA-Ar total scores of day 4− 9. 
Thus, 11 studies were incorporated in the meta-regression and the final 
unit of data analysis was the comparison of the cumulative mean CIWA- 
Ar total scores of the two phases of the course of AWS. 
Fig. 1. PRISMA flow diagram. 
Abbreviations: AWS: alcohol withdrawal syndrome; CIWA-A: Clinical Institute Withdrawal Assessment for Alcohol; CIWA-Ar: Clinical Institute Withdrawal 
Assessment for Alcohol – Revised; CIWA-B: Clinical Institute Withdrawal Assessment for Benzodiazepine; contrast: unit of data analysis. 
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2.3. Statistical analysis 
Analyses were computed using a random-effects model. We also 
assessed the existence of publication bias, the calculation of effect sizes, 
the subgroup analysis and moderator analysis. All analyses were con-
ducted with the use of the Comprehensive Meta-Analysis Software 3.0 
(Comprehensive Meta-Analysis Software (CMA), 2020). For the calcu-
lations, the means and standard deviations of the CIWA-Ar total scores 
following the course of treatment were collected. In case they were 
documented, the following demographic (e.g. gender or age) and 
alcohol-specific data were gathered: duration of alcohol consumption 
and alcohol dependence, and alcohol consumption in grams. However, 
these data were reported differently in the articles and many were 
missing, these collected data could not be analysed as moderator vari-
ables in the final analysis. 
The unit of data analysis was the comparison of the cumulative mean 
CIWA-Ar scores of two phases in the course of AWS treatment. The 
means and standard deviations of the first 9 days of AWS treatment were 
collected from each study and were separated into two measurement 
intervals reflecting on to the first and last phase of AWS. The first phase 
of AWS was day 1− 3, the last phase of AWS was day 4− 9 and the means 
of these days were averaged. If there were missing daily data, then 
averaging was done without them. In the study of Johnston et al. (1991), 
only 1, 2, 7 days were reported, then for the first phase we calculated the 
means and standard deviations of day 1 and 2, and the second phase was 
the seventh day. Similarly, in the study of Addolorato et al. (1999), the 
means and standard deviations of the CIWA-Ar total scores of day 1, 2 
and 3 were calculated for the first phase and day 4 and 5 were calculated 
for the second phase. Sengul et al. (2009) reported only data of day 1, 4 
and 7 of the CIWA-Ar scores, therefore the day 1 mean and standard 
deviation were the unit of analysis of the first phase and the means and 
standard deviations of CIWA-Ar scores of day 4 and 7 were averaged for 
the second phase. In case of some studies reporting only the CIWA-Ar 
total score of day 1 and 7, only the CIWA-Ar total score of the 1st day 
was used for the first phase and the CIWA-Ar total score of the 7th day 
was used for the second phase (Cavus et al., 2012; Heberlein et al., 2015, 
2014, 2010, 2017; Sönmez et al., 2016). 
In case of two studies (Chourishi et al., 2010; Girish et al., 2016), 
nBDZ was compared to lorazepam and chlordiazepoxide, and in the 
study of Addolorato et al. (1999) BZD was compared to γ-hydroxybu-
tyric acid, thus these studies yielded two comparison pairs for analysis. 
Publication bias was estimated based on visual/graphic examination 
of the funnel plots, and the Begg and Mazumdar’s rank correlation test 
(Begg and Mazumdar, 1994) and Egger’s regression (Egger et al., 1997) 
were calculated to estimate publication bias. Asymmetry was regarded 
as significant if the p-value was < 0.05 in the Begg and Mazumdar test 
and the p-value was < 0.1 in the Egger’s test. If the standardized residual 
of a study was greater than 3.29, the study was considered an outlier 
(Shiffler, 1988). Therefore, two studies (Chourishi et al., 2010; Girish 
et al., 2016) were excluded based on standardized residuals. Thus, the 
previously identified 9 studies yielded 10 comparison pairs for the 
present meta-analysis (Pribék et al., 2020). 
Heterogeneity was evaluated with the Q-test and I2 test to explore 
whether the results of the studies were consistent. Significant p-value in 
the Q-test and value over 75 in the I2 test meant a statistically signifi-
cant, considerable heterogeneity in the sample. To examine the differ-
ences between the BZD and the nBZD groups, sampling variances 
(v1 for the BZD and v2 for the nBZD group) were calculated with the 










By this, the results of the two treatment groups were comparable and 
were contrasted with the standard normal test statistics with the present 





If |z | ≥ 1.96, the differences of the groups were considered statisti-
cally significant. Moderator and covariate analysis were calculated to 
explore the moderating effects of age and the proportion of males on the 
course of AWS. Significant effect was detected if the p value was < 0.05. 
2.4. Prisma guidelines 
This systematic review and meta-analysis are presented in accor-
dance with the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) (Moher et al., 2009) statement, and its 
reporting is in accordance with the guidelines of meta-analyses in 
epidemiology described by Stroup and his colleagues (Stroup et al., 
2000). 
3. Results 
3.1. Publication bias and heterogeneity 
Based on the results of the visual/graphic examination, symmetric 
funnel plots were observed in the BZD (Fig. 2) and nBZD subgroups 
(Fig. 3), while the Egger’s test for intercept also indicated symmetry 
(Intercept = − 4.774, p = 0.177). Based on the Begg and Mazumdar test, 
publication bias was not detected neither in the BZD group (Kendall’s 
tau = − 0.5, p = 0.221) nor in the nBZD (Kendall’s tau = − 0.5, p = 0.22) 
group. 
Significant heterogeneity was expected due to the methodological 
differences in the studies, thus significant heterogeneity was found in 
the sample (Qw (9) = 32.946, p < 0.001) and the two subgroups also 
differed in terms of heterogeneity (Qw (1) = 9.768, p = 0.002), while the 
I2 test indicated a moderate level of heterogeneity in the BZD (I2 =
71.333) and the nBZD groups (I2 = 56.639). 
3.2. Comparison of the course of AWS measured with the CIWA-Ar total 
scores in the BZD and nBZD groups 
The nine studies which met the inclusion criteria and yielded 10 
comparison pairs are detailed in Table 1. 
A total of 423 patients were analyzed and classified into two groups 
based on received pharmacotherapy. Since Addolorato et al. (1999) 
yielded one comparison pair in the BZD and one in the nBZD group, 5 
articles yielding 5 comparison pairs were classified into the BZD group 
(N = 127) and 5 articles resulting in 5 comparison pairs were listed in 
the nBZD group (N = 296). The random effects model showed a decrease 
between the two measurement intervals, thus indicated the decrease of 
the CIWA-Ar scores during the course of AWS (BZD: d = –1.361; CI: 
–1.829 < δ < –0.893; nBZD: d = –0.858; CI: –1.073 < δ < –0.643) 
(Fig. 4). For the comparison of the results of the two groups, sampling 
variances were calculated for the BZD (v1 = 0.215) and the nBZD (v2 =
0.106) group, from which the z-score was computed (z = − 1.532). This 
indicates that there is no statistically significant difference between the 
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BZD group and the nBZD group. For assessing the role of the proportion 
of males and age in the samples, moderator analysis was conducted; data 
regarding the proportion of males were available for 10 comparison 
pairs and 9 reported ages. No significant effect was detected based on 
the model, therefore the proportion of males (coefficient: 0.02; p = 0.48) 
and the age (coefficient: 0.10; p = 0.216) did not have any moderating 
effect concerning the change of the total CIWA-Ar score. 
4. Discussion 
In the present study, a systematic literature search-based meta- 
analysis was conducted on the effects of different pharmacotherapy- 
based treatment approaches of AWS evaluated by the change of the 
total scores of the CIWA-Ar during the course of AWS. This measurement 
tool was selected, since the major treatment protocols refer to it as a gold 
standard in the objective follow-up during the course of AWS. A total of 
10 comparison pairs in 9 articles were analyzed including 423 patients’ 
data. Our results showed a significant decrease of CIWA-Ar total scores 
in the course of AWS indicating that this tool appropriately followed the 
course of AWS (as a means of the ecological validity of this measure). 
Furthermore, the group receiving BZD treatment did not show a 
significant difference from the nBZD group from the perspective of the 
course of AWS measured by the CIWA-Ar total scores. 
Considering the relatively high morbidity of patients with AWS, the 
main goal during the treatment of AWS besides reducing the symptoms 
of withdrawal is to prevent the development of DT. It has been previ-
ously demonstrated that complicated or uncomplicated AWS occur in 
about 50% of AUD patients (de Wit et al., 2010; Lau et al., 2008; San-
nibale et al., 2005). Unfortunately, DT, characterized by the fluctuation 
of consciousness, perceptual abnormalities, agitation and severe auto-
nomic symptoms (Driessen et al., 2005; Jesse et al., 2017; Mirijello et al., 
2015), as the most severe complication of treated or untreated with-
drawal syndrome, is presented in about 5% of patients hospitalized with 
AWS (McKeon et al., 2008; Mirijello et al., 2015). Its occurrence during 
AWS is associated with a worse prognosis, further, it may lead to death 
in approximately 1–5% of patients (Schuckit et al., 1995). 
For monitoring the progress and course of withdrawal, psychometric 
tools such as the CIWA-Ar have paramount importance during the 
management of AWS. For instance, it has been evaluated that the CIWA- 
Ar is a fundamental psychometric tool used by clinicians during 
symptom-triggered therapy of AWS (Cassidy et al., 2012; Daeppen et al., 
2002; Hoffman and Goldfrank, 1989; Ismail et al., 2019; Jaeger et al., 
Fig. 2. Funnel plot of standard error by standardized mean differences in the benzodiazepine (BZD) group.  
Fig. 3. Funnel plot of standard error by standardized mean differences in the non-benzodiazepine (nBZD) group.  




Characteristics of the studies in the benzodiazepine and non-benzodiazepine subgroups included in the quantitative analysis (meta-analysis).  
Study Country Pharmacological 
intervention 
Dosing of medications CIWA-Ar 
mean score, 











Average duration of 
alcohol consumption 
in years (SD) 
Average duration of 
alcohol dependence 






et al. (1999) 
Italy diazepam 0.5− 0.75 mg /kg body 
weight for 6 days, tapering the dose 





30 (83.33) 44.3 (10.9) n/a 15.4 (10.2) 196 (139.7) 
Cavus et al. 
(2012) 
Turkey diazepam tapering the dose over 7 days 
(minimum: 30 mg, maximum: 40 mg 
on day 1) 
18.8 (9.9) 1 (0.9) 31 (100) 42.8 (7.9) 17.6 (6.5) n/a 164.2 (46.2) 





diazepam 40 mg (10 mg every six 
hours for 24 h) 
7.6 (4.2) 4.9 (2.8) 16 (100) 45.1 (11.2) 25.2 (2.8) n/a n/a 
Sengul et al. 
(2009) 
Turkey diazepam and 
memantine placebo 
standard dose of 30 mg/day, tapering 
the dose daily by 5 mg, discontinued 
at the end of the sixth day 
22.94 (7.47) 6.41 (3.45) 16 (100) 43.6 (7.3) 11.5 (5.7) n/a n/a 
Sönmez et al. 
(2016) 
Turkey diazepam based on the withdrawal symptoms, 
tapered gradually, cumulative dosage 
during AWS: M = 318.09 (SD 
=161.49 mg) 
9.79 (5.64) 4.41 (3.62) 34 (100) 45.44 (8.98) 16.32 (8.82) n/a n/a 
NON-BENZODIAZEPINE SUBGROUP 
Addolorato 
et al. (1999) 
Italy γ-hydroxybutyric 
acid (GHB) 
50 mg/kg body weight for 10 days 8.83 (3.5) 3.545 (2.86) 30 (86.67) 41.7 (10.4) n/a 16 (10.2) 214 (124.7) 
Heberlein 
et al. (2010) 
Germany oxcarbazepine based on the withdrawal symptoms, 
tapered gradually 
(minimum 300 mg, maximum: 1200 
mg on day 1, M = 770 mg, SD = 244 
mg) 
clomethiazole, prometazin in some 
cases 
15.32 (3.48) 12.87 (2.56) 82 (100) 43.59 (7.84) 8.85 (7.38) n/a 193.27 (85.59) 
Heberlein 
et al. (2014) 




M =772.34 mg (SD = 223.31); 
day 7: 
M =652.17 mg (SD = 270.59) 
clomethiazole dosage: day 1: 
M = 8.47 capsules (SD = 4.11) 
day 7: M = 0.13 capsules (SD = 0.65) 
15.74 (3.64) 13.30 (2.76) 30 (100) 42.98 (6.91) 9.37 (6.92) n/a 199.3 (91.61) 
Heberlein 
et al. (2015) 
Germany carbamazepine and 
clomethiazole 
carbamazepine dosage: day 1: 
M =710.97 mg (SD = 299.91) day 7: 
M =551.877 mg (SD = 340.51) 
clomethiazole dosage: day 1: 
M = 5.77 capsules (SD = 5.89) day 7: 
M = 0.08 capsules (SD = 0.52) 
15.68 (4.22) 12.84 (2.72) 99 (100) 42.9 (9.01) 9.79 (7.67) n/a 195.43 (81.61) 
Heberlein 
et al. (2017) 
Germany carbamazepine and 
clomethiazole 
n/a 15.46 (4.05) 12.79 (2.69) 55 (100) n/a n/a n/a n/a  
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2001; Saitz et al., 1994). Furthermore, the reliability and validity of 
CIWA-Ar has been previously confirmed in several psychometric ana-
lyses revealing the robustness of the measurement tool (Bakhla et al., 
2014; Higgins et al., 2019; Lázár et al., 2019; Pittman et al., 2007; 
Sullivan et al., 1989; Zhuo et al., 2010). However, some research groups 
formerly suggested shorter versions of the CIWA-Ar and other tools for 
identifying and following the signs of withdrawal (Elefante et al., 2020; 
Gray et al., 2010; Lindner et al., 2019; Maldonado et al., 2014), which 
were excluded from the present analysis, since available literature data 
indicate that the original CIWA-Ar is the most important and reliable 
scale in the diagnosis and treatment of AWS. 
If AWS is uncomplicated, the symptoms decrease continually as the 
disease progresses, which is facilitated by the adequate pharmacological 
approach. BZD is a commonly used pharmacological intervention and is 
the first choice of drug therapy in the standard treatment of AWS 
(Daeppen et al., 2002). BZDs, besides their pivotal role in the treatment 
of all phases of AWS, may have severe side effects such as cardiopul-
monary depression, toxicity and addiction. Thus, in the last few decades, 
several studies have suggested that nBZD agents may be alternative 
choices during the course of AWS. Although, nBZDs such as carbamaz-
epine or baclofen in general are used in the treatment of mild or mod-
erate AWS (Malcolm et al., 2001), several reports have showed that 
carbamazepine reduces post-treatment alcohol consumption and pre-
vents the rebound of withdrawal symptoms (Gentry et al., 2002; Mal-
colm et al., 2001; Stuppaeck et al., 1994). Moreover, some reports 
suggested that the relapse rate of AUD patients is higher among 
BZD-treated patients compared to nBZD-treated patients (Maldonado, 
2017). Our findings indicating that the decrease of the total scores of the 
CIWA-Ar is similar between the BZD and nBZD subgroups, which is in 
agreement with recent works demonstrating that symptoms of AWS 
were reduced with a similar tendency by using nBZD agents compared to 
BZD-based therapy (Addolorato et al., 1999; Lucht et al., 2003; Sychla 
et al., 2017). In addition, some studies have demonstrated that BZD 
treatment itself might even be a risk factor for the development of DT 
(Gaudreau et al., 2005; Kudoh et al., 2004; Maldonado, 2008). In 
addition, our results are consistent with the previous meta-analyses 
regarding pharmacotherapy, in which BZDs were proved to be more 
effective than placebo (Mayo-Smith, 1997), but nBZDs showed similar 
effectiveness compared to BZDs (Amato et al., 2011, 2010; Holbrook 
et al., 1999). Previous scientific literature also reflected on that general 
symptoms were similarly reduced (Lucht et al., 2003). Although, it is 
important to note that from the studies included in the present 
meta-analysis, only Addolorato et al. (1999) addressed the issue of side 
effects. However, developing adverse effects were not consistent in the 
literature in the cases of BZD and nBZD treatments. For example, some 
articles suggest that the adverse effects were less common with nBZDs 
than with BZDs (Addolorato et al., 1999; Sychla et al., 2017). On the 
other hand, a meta-analysis (Holbrook et al., 1999) showed no signifi-
cant differences between BZDs and nBZDs regarding adverse effects. 
Additionally, several limitations of the present findings should be 
taken into account. From a clinical point of view, the course of AWS 
takes 5–10 days (McKeon et al., 2008; Mirijello et al., 2015); however, in 
this study, only two measurement intervals were identified and could 
statistically be compared, using the aggregated means of CIWA-Ar total 
scores. These two measurement intervals (day 1− 3 and day 4− 9) were 
contrasted, since empirical studies using the total scores of CIWA-Ar 
generally lacked the comprehensive reporting of the daily data of the 
means and standard deviations of the CIWA-Ar total scores. This 
methodological diversity presented in the publications lead to the 
relatively smaller sample size and comparable units of data. 
Based on the results, the CIWA-Ar follows the course of withdrawal, 
but the total score includes several factors (e.g. delirious, autonomic and 
non-specific factors) (Bakhla et al., 2014), so it can be assumed that 
these factors are not equally sensitive to the therapy. Moreover, the 
medications may have caused changes in the patient’s conditions, but it 
was not conceivably explored due to the two measurement intervals 
utilized in the present analyses. It is important to note that in the present 
meta-analysis, only articles written in English language were incorpo-
rated. Several strategies exist for handling non-English studies besides 
omitting them, but in the present systematical review-based meta--
analysis, papers written in different languages than English were auto-
matically excluded, which may cause language bias (Grégoire et al., 
1995). On the notion of the potential presence of bias, it should also be 
noted that the studies incorporated in the present analyses were mostly 
conducted in the European region (especially in Germany and Turkey), 
and they predominantly examined men (Addolorato et al., 1999), which 
could potentially cause geographical and gender bias (Holdcroft, 2007). 
Another limitation is the significant heterogeneity observed in the 
sample, which may be reasoned with several factors. Firstly, different 
medications and dosing were in the nBZD subgroup (for a detailed list of 
medications and dosages, see Table 1). For instance, the standard dosage 
of diazepam was 30 mg/day in the study of Sengul and his colleagues 
Fig. 4. Forest plot of standardized difference in means for the benzodiazepine (BZD) and the non-benzodiazepine (nBZD) subgroups.  
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(Sengul et al., 2009), but in the study of Johnston et al. (1991), 40 
mg/day of diazepam was given to the patients. Furthermore, the time 
during which patients actually received these medications also altered in 
the studies, for example diazepam was tapered over 6 (Sengul et al., 
2009) or 7 (Cavus et al., 2012) days, respectively. Other alcohol-related 
factors, such as the duration of problematic alcohol consumption and 
alcohol dependence or the consumed amount of alcohol in grams could 
also serve as moderating variables in the severity and course of AWS 
(Pristach et al., 1983; Schuckit et al., 1995). Despite the gathering of 
alcohol-specific data in the present study, they could not be incorpo-
rated in the moderator or covariate analysis due to insufficient data 
available. Therefore, future empirical research should elucidate and 
report these variables in order to take into account their possible con-
founding effects. Based on the DSM-5 criteria, the most significant 
symptoms of AWS are monitored by the CIWA-Ar. However, other 
symptoms can occur during the course of AWS, which can be measured 
by other instruments as well. CIWA-Ar is an abbreviated version of the 
Clinical Institute Withdrawal Scale - Alcohol (CIWA-A), and the original 
instrument includes additional symptoms, such as vital signs, seizures 
and quality of contact (Shaw et al., 1981). Other measurement scales, e. 
g. the Alcohol Withdrawal Symptom Checklist (AWSC) further monitors 
the symptoms of sleep disturbance, poor appetite, depression, asthenia, 
craving, muscle cramps, nervousness and irritation (Pittman et al., 
2007). Since CIWA-Ar has not operationalized the previously listed 
symptoms, this represents a potential limitation regarding the inter-
pretation of the BZD and nBZD group differences described in the pre-
sent meta-analysis. 
On this notion, there is a great need of further empirical and also 
meta-analytical data to address the potential effects of alcohol-specific 
variables on the course and treatment of AWS. More empirical 
research would be vital to further explore the role of the CIWA-Ar in the 
different symptom-based treatment regimens of AWS, with the incor-
poration of such additional data (e.g. alcohol-related factors) that might 
be important in gaining a more detailed picture of the clinical man-
agement of AWS. 
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